Resistance towards the proteasome inhibitor bortezomib is poorly understood. We adapted the HL-60, ARH-77 and AMO-1 cell lines (myeloid leukemia, plasmocytoid lymphoma, myeloma) to bortezomib exceeding therapeutic plasma levels, and compared characteristics of the ubiquitin-proteasome system, alternative proteases and the unfolded protein response (UPR) between adapted cells and parental lines. Adapted cells showed increased transcription rates, activities and polypeptide levels of the bortezomib-sensitive b5, but also of the b2 proteasome subunit and consistently retained elevated levels of active b1/b5-type proteasome subunits in the presence of therapeutic levels of bortezomib. Bortezomib-adapted HL-60 cells showed increased expression and proteasome association of the 11S proteasome activator, and did not accumulate poly-ubiquitinated protein, activate the UPR or UPR-mediated apoptosis in response to bortezomib. The rate of protein biosynthesis was reduced, and the transcription of chaperone genes downmodulated. We did not observe major changes in the activities of TPPII, cathepsins or deubiquitinating proteases. We conclude that different types of bortezomib-adapted cell lines, including myeloma, show similar patterns of changes in the proteasomal machinery which result in residual proteasome activity in the presence of bortezomib and a quantitative balance between protein biosynthesis and destruction.
Introduction
Proteasome inhibition has emerged as a new therapeutic option against cancer. 1 The proteasome inhibitor (PI) bortezomib is approved for the treatment of multiple myeloma and mantle cell lymphoma, and further clinical applications of bortezomib as an antineoplastic agent are under investigation. [2] [3] [4] Bortezomib disrupts the equilibrium between protein biosynthesis and protein degradation, which ultimately results in apoptosis triggered through the unfolded protein response (UPR). However, not all types of malignancies are bortezomib-sensitive, and both primary and secondary bortezomib resistance occur in myeloma. 4 Little is known about the molecular changes in the proteolytic network when bortezomib resistance is acquired.
The proteasome is responsible for the bulk degradation of (mostly) poly-ubiquitinated cytosolic proteins. 5, 6 Three types of subunits in the inner b rings of the 20S core particle carry the proteolytic 'caspase-' (b1), 'trypsin-' (b2) and 'chymotrypsin-like' (b5) activities.
Alternative 'immunoproteasome' active subunits (b1i, b2i, b5i) may be expressed. All active subunits are threonine proteases that can be targeted by several inhibitors with differing individual specificities. 7 ATP-dependent substrate recruitment, deubiquitination and unfolding are executed by the 19S regulatory complex, which together with the 20S core forms the 26S proteasome. Alternative regulatory complexes exist, including the interferon-inducible 11S activator, also called proteasome activator (PA) 28.
Recruitment of putative substrates to the proteasome is regulated by the balance between E3 ubiquitin (Ub) ligases and deubiquitinating enzymes, including the Ub-specific proteases (USP) and Ub C-terminal hydrolases. 5, [8] [9] [10] Substrate recruitment in part occurs through ER-associated degradation, where misfolded protein is retro-translocated to the cytosol for proteasomal degradation. 11 Accumulation of misfolded proteins in the ER induces the UPR, resulting in a decreased rate of general transcription, whereas protein expression of selected chaperones (for example, GRP78/BiP, heat-shock proteins) is increased. 12 Prolonged activation of the UPR finally leads to programmed cell death by several pathways, including a pathway mediated by caspase 4 and the pro-apoptotic protein GADD153/CHOP. 12, 13 Proteasome inhibition by bortezomib leads to the accumulation of misfolded protein especially in the ER, which triggers the UPR-mediated apoptosis.
14 In PI-resistant cells, alternative proteases or proteolytic systems may take over tasks of the proteasome, as suggested for lymphoma cells adapted to the irreversible proteasome inhibitor 4-hydroxy-5-iodo-3-nitrophenylacetyl-(Leu) 3 vinyl sulfone (NLVS), where the activity of another multi-subunit protease complex, tripeptidyl peptidase II (TPPII), was upregulated and rescued cells from PI-challenge. 15, 16 A significant amount of protein breakdown also occurs in lysosomes, mostly mediated by cathepsins. 17 Adaptive changes in the lysosomal proteolytic system may similarly contribute to bortezomib resistance.
Biology-driven strategies to overcome bortezomib resistance include the targeting of alternative active sites or proteins associated with the proteasome, combining bortezomib with agents that sensitize for UPR-mediated apoptosis, or combining bortezomib with inhibitors of putative proteolytic 'rescue'-pathways, such as TPPII. To further guide such approaches, we adapted three different types of cell lines, including a myeloma cell line, to bortezomib to characterize the fundamental changes in the proteolytic network of malignant cells with acquired bortezomib resistance.
Materials and methods
For a more detailed description, please refer to the Materials and methods section in Supplementary Information.
Cell culture, lysis and immunoblot
Cell lines were cultured in FCS-supplemented RPMI-1640 with penicillin/streptomycin. Medium for adapted cells additionally contained 20 nM bortezomib (Ortho Biotech, Neuss, Germany). All antibodies except those against different USP were obtained commercially.
Metabolic labeling
For quantification of protein biosynthesis, cells were labeled with 35 S-methionine/cysteine and the radioactivity incorporated into the protein fraction of cell lysates was measured using a scintillation counter.
Activity assays
Active site-directed probes were employed for (semi-) quantitative assessment of protease activities: labeling of active proteasome subunits was performed in live cells with the proteasome-specific affinity probes MV151 or dansyl-sulfonamidohexanoyl-(6-aminohexanoyl) 2 -(Leu) 3 vinyl sulfone, as described. 18, 19 Cell lysates were separated by SDS-PAGE. The fluorescent probe MV151 allows for visualization of proteasome activities by scanning the gel for fluorescence of its bodipy moiety. Quantification of fluorescent bands was performed using the program AIDA.
Immunoprecipitation
For immunoprecipitation of proteasome, cell lysates were incubated with anti-a2-agarose beads (Biomol, Hamburg, Germany) in IP buffer (25 mM Tris-HCl pH 7.3, 10 mM KCl, 0.5 mM EDTA, 2 mM MgCl 2 , 1mM DTT, 1 mM ATP, 5% glycerol). Beads were washed with 0.1 M NaCl in IP buffer and eluted with 2 M NaCl in IP buffer (without DTT, ATP, glycerol). Eluates were concentrated by ultrafiltration and analyzed by SDS-PAGE and immunoblot.
Cytotoxicity assay
Cytotoxicity of drugs was determined by an MTS assay (Promega, Mannheim, Germany) and absorbance measured at 492 nm. Results represent mean values from triplicates.
Results

Myeloma cell lines can be adapted to bortezomib
In analogy to the bortezomib-adapted HL-60a leukemia cell subline reported earlier, 20 we adapted the myeloma cell line AMO-1 and the plasmocytoid lymphoma-type subline ARH-77 to bortezomib by continuous incubation with increasing concentrations of the drug. The subclones HL-60a, AMO-1a, ARH-77a showed an IC 50 of 4600, 4160 and 500 nM, respectively, compared to 30, 8 and 20 nM for the parental cell lines (Figures 1a-c) , corresponding to a consistent at least 20-fold increase in the tolerated bortezomib dose. When HL-60a cells were grown without bortezomib for 14 days (HL-60a 14d) and then re-challenged by addition of the drug, cell viability was identical to HL-60a cells (Figure 1a ), indicating that bortezomib-adapted cells undergo a persistent adaptation process.
Bortezomib-adapted cells show similar patterns of changes in active proteasome subunits
To characterize the activity profile of proteasome subunits, we used the cell-permeable, activity-specific proteasome affinity label MV151. In agreement with our previous observations in HL-60a cells ( 20 , Supplementary Figure S1 ), labeling of proteasome active subunits in intact HL-60a cells confirmed the upregulation of both the b1/b5-type and the b2-type of proteasome activity (Figure 2a) . Similarly, an increase in active b2-type of subunits was also observed with ARH-77a cells and AMO-1a cells (Figure 2b ). However, although AMO-1a cells also showed a sizable increase in active b1/b5 subunits, ARH-77a cells showed no such change. HL-60a, ARH-77a and AMO-1a cells all retained higher levels of residual active b1/b5 proteasome subunits in the presence of bortezomib than control cells treated with the drug. This bortezomib-induced change in the proteasomal activity pattern persisted when HL-60a cells were incubated in bortezomib-free medium (wash out) for up to 7 days, either with or without re-challenge with pulsed bortezomib (Supplementary Figure S1 ).
Bortezomib-adapted cells are uniformly resistant to b1/ b5-targeted proteasome inhibitors but show variability in their sensitivity towards pan-proteasome inhibitors
To establish the selectivity of bortezomib resistance in bortezomib-adapted cells, the different cell lines were challenged with different types of proteasome inhibitors as well The probe covalently binds to the b1, b2, b5 proteasome subunits in an activity-dependent fashion. After cell lysis and separation by gel electrophoresis, MV151-labeled active proteasome subunits (b1, b2, b5) were detected using a fluorescence scanner. Cells incubated with the proteasome inhibitor ZL 3 VS were used as a negative control. Protein loading was assayed in a western blot for GAPDH. (b) ARH-77, AMO-1 and bortezomib-adapted ARH-77a and AMO-1a cells were treated with 20 nM bortezomib or 50 mM NLVS (negative control) for 16 h, before incubation with the MV151 probe for proteasomal subunit activities. Active subunits of the proteasome and immunoproteasome (i) were detected as described above. Protein loading was assayed by western blot for b-actin. (c) Quantification of active proteasomal subunits from bortezomib-adapted and non-adapted cells. Signal intensities of the fluorescent activity-based probe were directly measured after separation by SDS-PAGE using a fluorescence laser scanner. Intensities of bands corresponding to the b2 (black bars) and b5/ b1 (striped bars) proteasomal subunits in untreated cells are shown normalized to band densities of their respective protein loading controls.
as with daunorubicin as a conventional cytotoxic drug control. The vinylsulfone-type inhibitors carboxybenzyl-(Leu) 3 vinyl sulfone (ZL 3 VS) and NLVS preferentially inhibit proteasomal b1/b5-type active subunits in an irreversible fashion, whereas the borate-type inhibitor bortezomib binds these targets in a reversible manner. Epoxomicin and lactacystin target all active subunits of both the constitutive and the immunoproteasome in an irreversible manner. As expected, the viability of all bortezomib-adapted cell lines was unaffected by 40 nM bortezomib, in contrast to the parental control lines (Figure 3 ). All three types of bortezomib-adapted cells showed a similar selectivity in tolerance for bortezomib, NLVS and ZL 3 VS, whereas lactacystin and epoxomicin were less selectively tolerated by the bortezomib-adapted cells. By contrast, HL-60 and ARH-77 cells showed only minor variability in the doseresponse relationship to daunorubicin between adapted cells and control cells, whereas AMO-1a cells were less sensitive towards daunorubicin than their parental line.
Upregulation and variation in the composition of proteasomes in bortezomib-adapted cells
To analyze the composition and expression of the proteasome in bortezomib-adapted cells in further detail, we first focused on HL-60a cells (Figure 4a ). The expression of immunoproteasome subunits showed no gross difference between bortezomibadapted and parental cells, and little effect was also observed for the non-active a4 subunit. Interestingly, the 11S activator a-subunit (PA28a) was upregulated in HL-60a cells, in contrast to the 19S subunit Rpn1. We did not detect changes on the polypeptide level that were directly related to either the addition of pulsed bortezomib or to the duration of the bortezomib washout phase in HL-60a cells, indicating that the changes observed on the polypeptide level were adaptive and not reactive in nature. The increased expression of the 11S polypeptide, in contrast to 19S, in HL-60a cells suggested a higher proportion of 11S-20S proteasome complexes in comparison to non-adapted cells. Indeed, using a 20S-directed antiserum, a significant amount of 11S polypeptide (PA28a) was co-immunoprecipitated with 20S proteasomes only from HL-60a cells, but not from the HL-60 parental line (Figure 4b ). Thus, bortezomib-adapted HL-60a cells contained higher levels of proteasome proteins and were also characterized by a larger fraction of proteasomes associated with the 11S activator protein. A similar change in the expression level of proteasome polypeptides was also observed in ARH-77a and AMO-1a cells: in particular the b2 and b5-types of polypeptides increased in the adapted cells, whereas an increase in b1 expression was only observed in AMO-1a cells (Figure 4c ).
Comparative gene expression analysis reveals upregulation of proteasomal subunits and downregulation of chaperones in bortezomib-adapted cells
To examine the transcription levels of proteasome genes, and to identify additional genes in the ubiquitin-proteasome system that may mediate resistance to proteasome inhibitors, we employed a comparative gene expression analysis of bortezomib-adapted and control cells. We used a commercial microarray, which contains 1270 genes associated with the ubiquitin-proteasome system. To focus on persistent (adaptive) cellular changes associated with resistance to PI and to exclude short-lived (reactive) effects of proteasome inhibition or residual bortezomib activity, HL-60a cells were kept in bortezomib-free culture for 3 days (HL60a 3d) before comparison to HL-60 cells. Supplementary Tables 1 and 2 include mean results of two independent experiments; only genes that consistently showed 41.7-fold homonymous changes were included. Based on this analysis, 23 genes of the ubiquitin-proteasome system were detected as upregulated in HL-60a cells (Supplementary Table 1) , and 34 as downregulated (Supplementary Table 2 ), compared to HL-60 control cells.
The top five genes with the highest increase in mRNA expression included the PA28 proteasomal activator b subunit. In general, we observed consistent upregulation of genes encoding proteasomal subunits (b1, b2 and a7 of the 20S proteasome), as well as of the a-and b-subunits of the PA28 (11S) proteasomal activator.
Among the 34 genes that were consistently downregulated in HL-60a cells, the top five genes included four genes that are linked to protein folding and reactions to misfolded protein accumulation: HSP40 and HSP70 heat-shock proteins (mean reduction 89 and 78%, respectively), the ER-resident homocysteine-responsive protein HERPUD1 (reduction 74%) as well as pro-apoptotic GADD153/CHOP (reduction 75%), which is induced during ER stress-mediated apoptosis. The quantitatively most significant results from this gene expression analysis fit into the following overall pattern: Genes indicating ER stress and activation of UPR-mediated apoptosis were consistently downregulated (HSPs and other chaperones, CHOP), whereas genes facilitating proteasomal degradation (expression of proteasome activators, subunits, ubiquitin and ubiquitin-like proteins) were upregulated.
HL-60a cells are characterized by reduced protein biosynthesis and failure to accumulate polyubiquitinated protein and to trigger ER stress-mediated apoptosis in response to bortezomib
Compared to untreated parental cells, adapted cells showed similar (ARH-77a, AMO-1a) or slightly reduced (HL-60a) growth kinetics in the absence of bortezomib. The presence of the therapeutic dose of 20 nM bortezomib did not substantially reduce the growth rate of the adapted cells (Figure 5a) . We compared the rate of protein biosynthesis in adapted vs nonadapted cells by metabolic labeling of newly synthesized proteins. Bortezomib-adapted HL-60a cells showed a 75% reduction of the rate of protein biosynthesis compared to parental cells. Activation of the UPR is known to reduce protein biosynthesis. Accordingly, the addition of 20 nM bortezomib led to a 40% decrease in the rate of protein biosynthesis in HL-60 cells, but not in HL-60a cells, indicating that bortezomib did not activate the UPR in HL-60a cells (Figure 5b ). Consistent with this interpretation, bortezomib treatment resulted in a dose-dependent increase in poly-Ub proteins in HL-60 cells, but not in HL-60a cells (Figure 5c ). Similarly, expression of the UPR-associated chaperone BiP, as well as of markers of UPR-mediated apoptosis (active caspase 4 and cleaved PARP-1), was not triggered by increasing concentrations of bortezomib in HL-60a cells. Together, these results illustrate that bortezomib treatment does not induce an imbalance between protein biosynthesis and protein destruction in HL-60a cells. This is not due to an increased expression and/or activity in compensating proteolytic systems like lysosomal proteases, TPPII, or ubiquitinspecific proteases, because we did not observe consistent changes in any of these systems in the bortezomib-adapted cells, and the inhibition of cathepsins or TPPII did not induce the accumulation of poly-ubiquitinated protein in HL-60a cells ( Supplementary  Figures S2 and S3) . Hence, changes in the expression, activity and composition of proteasomes together with a decreased rate of protein biosynthesis are the major features characterizing the homeostasis of proteins in bortezomib-adapted cells.
Discussion
We have little insight into the cell biology of resistance against proteasome inhibitors. Most of the information available is obtained from studies analyzing individual non-myeloma type of cell lines adapted to standard laboratory-use proteasome inhibitors in vitro. The current study is the first to demonstrate that (i) adaptation to bortezomib can indeed be achieved in a myeloma cell line, that (ii) the adaptation to bortezomib induces similar patterns of changes in the proteasome system in different types of cell lines and that (iii) bortezomib-adapted cells reduce their rate of protein biosynthesis and do not activate the UPR upon exposure to bortezomib.
Adaptation of a myeloma cell line or a plasmocytoid lymphoma cell line towards bortezomib or other proteasome inhibitors has not been reported to date. It has been speculated that due to the special biology of the protein biosynthesis and quality control machinery in myeloma cells such an adaptation might not be possible. 21 The emergence of bortezomib-resistant myeloma in the clinical setting challenges this assumption. Our data demonstrate that myeloma-type AMO-1 cells and plasmocytoid-type lymphoma cells ARH-77 can be adapted towards high bortezomib concentrations, resulting in a more than 20-fold increase in the respective IC 50 of the drug. These bortezomib-adapted myeloma/plasmocytoid lymphoma cell lines proliferated at a similar rate compared to their parental lines, independently of the absence or presence of bortezomib.
Affinity labeling of active proteasome subunits using a cellpermeable activity-based probe allows the assessment of the active proteasomal subunits in live cells. The use of the fluorescent probe MV-151 enables a quantitative detection of the fluorescence signal, which selectively decorates active proteasome subunits, directly from the SDS-PAGE. This method eliminates limitations of peptide-based fluorogenic substrates for assessing proteasome activity, because the latter are not enzyme-specific and require disruption of the cells prior to analysis. We therefore here present the first quantitative measurement of changes in active proteasome subunits in intact bortezomib-adapted cells. Our data illustrate that bortezomibadapted cells undergo qualitatively quite similar changes in their active proteasome subunits, albeit with significant quantitative differences: they increase b2 activity from 50% to nearly 10-fold, and similarly, activity signals for the b1/b5-type of activities were differentially increased in two adapted cell lines. These increases at least in part result from the increased transcription rates of proteasome genes and expression of the respective polypeptides, as observed by western blot and gene expression analysis. The failure to detect a significant increase in the amount of active b1/b5-type of subunits in ARH-77a cells may in part reflect the fact that these two subunits can barely be distinguished by SDS-PAGE, whereas the respective comparison of proteasome polypeptides by western blot analysis shows an increase in b5 expression, but not in b1 expression. Importantly, all adapted cell types retained detectable activity of the targeted b1/b5 active sites in the presence of 20 nM bortezomib, in contrast to control cells, underscoring the apparent need for residual proteasome activity.
To date, different individual cell lines have been adapted to increased bortezomib levels and different changes in proteasome activity have been reported. [21] [22] [23] [24] Because of the different types of analysis, assay conditions, as well as differences in generating the individual bortezomib-adapted cell clones, it is difficult to assess to what extent bortezomib resistance follows a more general and qualitatively reproducible reaction pattern in different cells. Mutations in the active center of the b5 polypeptide have been repeatedly reported, which in part did, and in part did not lead to increased chymotryptic activity with and without overexpression of individual proteasome subunits. The currently most comprehensive report 21 analyzes different clones of one myeloid leukemia cell line, which show overexpression of b1, 2 and 5 polypeptides, and an increase in active b2, but a decrease in active b1 and b5 by intracellular affinity labeling. This discrepancy is explained by a point mutation in the active center of b5, which likely interferes with binding of the probe. A different point mutation in the active center of the b5 polypeptide has been observed in T-cell lymphoma-type Jurkat cells, together with an increase in transcription of the respective gene. 22, 23 Here, we directly compare the adaptive changes in three different cell lines generated under identical conditions, and observe an increased expression and also increased active species of the targeted as well as of the non-targeted active proteasome subunits. This argues that the resistance towards proteasome inhibitors is characterized by a mostly uniform reaction pattern consisting of the upregulation of proteasome transcription, expression and activity, which is triggered by proteasome inhibition. The increase in labeled b1/b5 activity observed in our study argues against mutations in the active center of the b5 polypeptide at least in AMO-1a and HL-60a cells.
In addition to increased proteasome active subunit expression, HL-60a showed increased expression of the 11S activator, both on the mRNA and protein levels, whereas no changes in the immunoproteasome levels were observed. Although higher levels of the IFN-g-inducible 11S activator without increased numbers of immunoproteasomes may be counter-intuitive, our results show that a higher portion of 11S is also bound to the 20S core particle in HL-60a cells. In contrast, Burkitt lymphoma cells adapted to bortezomib expressed higher levels of constitutive 20S and 19S subunits, whereas immunoproteasome and 11S subunits were downregulated. 24 However, Burkitt lymphoma relies less on proteasome activity due to its exceptionally high activity of the cytosolic protease TPPII, so that different cell types may well differ in this respect.
Proteasome inhibition by bortezomib triggers the UPR due to the accumulation of unprocessed, misfolded protein, which ultimately results in UPR-mediated apoptosis, when sufficient ER stress is applied. HL-60a cells show a number of features suggesting that bortezomib fails to induce ER stress or that the level of ER stress is at least minimized:
In a striking difference to the hyperproliferation of bortezomib-adapted Burkitt lymphoma cells, 24 HL-60a cells markedly reduced their rate of protein biosynthesis, although they proliferated at only slightly decreased speed. First and foremost, the combination of reduced protein synthesis and increased baseline proteasomal activity is likely to facilitate cellular homeostasis in the presence of bortezomib (through a decrease in production of defective ribosomal products and residual proteolytic activity). Also, the reduction of gene expression of E3 Ub ligase components observed in HL-60a cells can be integrated into this model: a downmodulation of the Ub conjugation machinery can be predicted to prepare a less substrate for degradation by the proteasome, thereby contributing to the balance between proteasome substrates and proteasome activity in the absence of the inhibitor. We observed less mRNA expression of the major HSP in HL-60a cells during bortezomib-free culture, indicating the basal levels of cellular stress and hence the need for chaperones is considerably lower in HL-60a than in control cells. Therefore, even when exogenous ER stress is applied in HL-60a cells, these cells may more easily upregulate chaperones to compensate the ER stress and to avoid UPR-mediated apoptosis.
When the proteasome is inhibited, alternative proteases (such as autophagy-mediating lysosomal proteases, or cytosolic TPPII) can compensate for the lack of proteasome activity. 15, 16, 25 We did not observe such an increased activity of TPPII using an assay based on a fluorogenic substrate. Also, we found no evidence for an increased activity of key lysosomal proteases such as cathepsins Z, B or S that may take over a part of the proteasome's function in HL-60a cells. Although we cannot formally exclude that protease activities not examined by us could be upregulated, the increase in proteasome activity together with the lack of effect of a TPPII inhibitor or leupeptin, which broadly inhibits cysteine and serine proteases, suggest to us that alternative proteolytic pathways are not key features that mediate the bortezomibadapted phenotype.
Bortezomib-adapted cells showed resistance towards different types of PI. This argues against the use of alternative proteasome inhibitors to target bortezomib-adapted cells. In contrast to their PI resistance, they remained sensitive to daunorubicin (as well as to further standard cytotoxic drugs, data not shown). Because daunorubicin is a substrate of multi-drug resistance transporters, resistance to bortezomib is unlikely to be mediated by increased drug efflux through these transport systems.
In summary, bortezomib-adapted cells can likewise emerge from myeloma, plasmocytoid lymphoma or myeloid leukemia cells and show similar patterns of changes in their proteasome biology. They combine a number of different features that are likely to make their UPR/proteasome system less vulnerable to bortezomib. Some of these features, such as upregulating or mutating the b5 subunit, are specific to the target of bortezomib, and may therefore be overcome by alternative proteasome inhibitors. However, other features like a general downregulation of protein biosynthesis and UPR chaperones, as well as the upregulation of the remaining active proteasome subunits, affect the entire UPR/proteasome system and are not specific for the inhibition of b5 by bortezomib. Therefore, in bortezomibadapted cells, targeting the proteasome/UPR machinery by alternative proteasome inhibitors and/or combination therapies of bortezomib with drugs that increase ER stress (such as HSP inhibitors, HIV protease inhibitors 26 ) or interfering with alternative proteolytic pathways (cathepsin inhibitors, autophagy inhibitors, TPPII-inhibitors) appear to be less promising strategies than the targeting of pathways entirely unrelated to the proteasome.
